Tag: Cancer: Lymphoma
FDA Approves First Biosimilar to Non-Hodgkin’s Lymphoma Drug
Truxima approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma
FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
Adcetris approved in combination with chemo to treat systemic anaplastic large cell lymphoma
Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression-free survival to 13.3 months versus 9.9 months for ofatumumab
Rituximab + Lenalidomide Effective in Follicular Lymphoma
Response rate, progression-free survival comparable to those seen with rituximab-chemotherapy
FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome
Lymphoma, Leukemia Survivors Have Increased Health Care Use
Survivors who are psychologically distressed use even more services than those who aren't
Early Intervention May Reduce Breast CA-Related Lymphedema
Bioimpedance spectroscopy monitoring with early interventions lowers need for aggressive treatment
Breast Implants Slightly Increase Risk of Breast ALCL
Implants tied to increased risk of anaplastic large-cell lymphoma; overall risk still very small
ASH: A+AVD Beats ABVD for Advanced Hodgkin’s Lymphoma
Lower combined risk of progression, death, or noncomplete response with A+AVD
ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas
Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma
